Cargando…

Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era

Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HPSCs) often results in myelosuppression that adversely affects patient health and quality of life. Currently, chemotherapy-induced myelosuppression is managed with chemotherapy dose delays/reductions and lineage-specific suppor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lyman, Gary H., Kuderer, Nicole M., Aapro, Matti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299941/ https://www.ncbi.nlm.nih.gov/pubmed/34307165 http://dx.doi.org/10.3389/fonc.2021.697908

Ejemplares similares

Myeloprotection with activated carbon in doxorubicin-treated rats
por: Gerashchenko, Bogdan I., et al.
Publicado: (2023)

Personalized cancer supportive care in COVID-19 era
por: Lyman, G.H., et al.
Publicado: (2020)

Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy
por: Atwal, Mandeep, et al.
Publicado: (2017)

COVID-19 vaccine effectiveness in patients with cancer: remaining vulnerabilities and uncertainties
por: Kuderer, Nicole M, et al.
Publicado: (2022)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

The strengths and limitations of meta-analyses based on aggregate data
por: Lyman, Gary H, et al.
Publicado: (2005)

Antiemetic and Myeloprotective Effects of Rhus verniciflua Stoke in a Cisplatin-Induced Rat Model
por: Kim, Hyo-Seon, et al.
Publicado: (2017)

Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer
por: Ghielmini, M, et al.
Publicado: (1999)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—introduction
por: Aapro, Matti
Publicado: (2018)

Crowdsourcing a crisis response for COVID-19 in oncology
por: Desai, Aakash, et al.
Publicado: (2020)

Myeloprotective Activity of Deoxyspergualin: Influence on Splenic Colony‐forming Cell Injury and Antitumor Activity of Mitomycin C in Mice
por: Nemoto, Kyuichi, et al.
Publicado: (1992)

Design and synthesis of coumarin-based organoselenium as a new hit for myeloprotection and synergistic therapeutic efficacy in adjuvant therapy
por: Patra, Arup Ranjan, et al.
Publicado: (2018)

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—concluding thoughts
por: Aapro, Matti
Publicado: (2018)

Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study
por: Culakova, Eva, et al.
Publicado: (2014)

Improving IBD outcomes in the era of many treatment options
por: Kobayashi, Taku, et al.
Publicado: (2023)

Supportive care in patients with cancer during the COVID-19 pandemic
por: Aapro, M., et al.
Publicado: (2020)

Myeloprotective activity of crude methanolic leaf extract of Cassia occidentalis in cyclophosphamide-induced bone marrow suppression in Wistar rats
por: Neboh, Emeka E, et al.
Publicado: (2015)

Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes
por: Belkacemi, Yazid, et al.
Publicado: (2018)

Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study
por: Sang, Yuting, et al.
Publicado: (2022)

Celecoxib may be a viable treatment option for breast cancer patients not treated with chemotherapy
por: Harris, Randall E., et al.
Publicado: (2022)

A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting
por: Hesketh, Paul J., et al.
Publicado: (2015)

Development of Approaches and Metrics to Measure the Impact and Improve the Clinical Outcomes of Patients With Frailty in the Era of COVID-19. The COMETA Italian Protocol
por: Silvestris, Nicola, et al.
Publicado: (2022)

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
por: Lustberg, Maryam B., et al.
Publicado: (2023)

Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer
por: Dómine Gómez, Manuel, et al.
Publicado: (2021)

Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy
por: Porceddu, Sandro V., et al.
Publicado: (2020)

Systemic Chemotherapy Including Ramucirumab in Combination With Pressurized Intra-Peritoneal Aerosol Chemotherapy Is a Safe Treatment Option for Peritoneal Metastasis of Gastric Cancer
por: Feldbrügge, Linda, et al.
Publicado: (2021)

Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma
por: Hu, Boyu, et al.
Publicado: (2018)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

Therapeutic Approaches for Acute Promyelocytic Leukaemia: Moving Towards an Orally Chemotherapy-Free Era
por: Xu, Zheng-Li, et al.
Publicado: (2020)

Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based survey
por: Aapro, Matti, et al.
Publicado: (2018)

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010)

Treatment patterns and outcomes in patients with non‐small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy‐induced/febrile neutropaenia: Results from the MONITOR‐GCSF study
por: Aapro, Matti, et al.
Publicado: (2019)

Establishment of an Immune Cell Infiltration Score to Help Predict the Prognosis and Chemotherapy Responsiveness of Gastric Cancer Patients
por: Jiang, Quan, et al.
Publicado: (2021)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Cervical Cancer Recurrence and Patient Survival After Radical Hysterectomy Followed by Either Adjuvant Chemotherapy or Adjuvant Radiotherapy With Optional Concurrent Chemotherapy: A Systematic Review and Meta-Analysis
por: Zhang, Yu-fei, et al.
Publicado: (2022)

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
por: Hussein, Maen, et al.
Publicado: (2021)

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
por: Boccia, Ralph, et al.
Publicado: (2022)

Precise prediction of the sensitivity of platinum chemotherapy in SCLC: Establishing and verifying the feasibility of a CT-based radiomics nomogram
por: Su, Yanping, et al.
Publicado: (2023)

Dose escalation via brachytherapy boost for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy and combined chemotherapy
por: Chao, Hsing-Lung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_44tiborpqvnq05sp992tv64agp